Infant AML patients (n = 197) displayed the following rearrangements: MLLT3 (n = 56; 28.4%), MLLT10 (n = 54; 27.4%), ELL (n = 30; 15.2%), AFDN (n = 3; 1.5%), AFF1 (n = 3; 1.5%), EPS15 (n = 2; 1.0%), MLLT1 (n = 2; 1.0%) and 16 other KMT2A rearrangements. This evidence concerns the gene KMT2A and acute myeloid leukemia.